Loading True North Map…
Canadian defence and dual-use directory
Loading the published organization directory.
Loading published organizations…
Avivo Biomedical is a Vancouver biotechnology company developing enzymes intended to reduce ABO blood-group incompatibility in donated blood and organs. The enzymes remove surface sugar markers that distinguish blood groups, with the aim of converting A, B and AB material toward a type-O profile. Avivo proposes adding them to blood-bag systems during collection and organ-preservation solutions during perfusion, fitting conversion into existing treatment workflows.
Its research spans distinct settings: type-A antigen removal from research donor kidneys during machine perfusion, transplantation of an enzyme-treated kidney into a human-decedent recipient, and laboratory conversion of type-A swine whole blood. These studies examine antigen removal and short-term responses; they do not establish an authorized treatment for living patients.
The company is working on enzyme manufacturing and clinical translation. Its June 2026 collaboration with Kemp Proteins addresses expression, purification and scalable upstream and downstream processes. A federal contribution supports production scale-up, preclinical studies and planned first-in-human trials. NATO DIANA lists Avivo in its 2026 Human Resilience and Biotechnology cohort with a proposed whole-blood conversion unit.
The business previously used ABOzymes and announced the Avivo name in September 2022. The current federal contribution identifies Avivo Biomedical Inc. as its legal and operating name.
The central development question is whether conversion remains effective and safe through the intended treatment workflow. In the human-decedent kidney experiment, the treated organ avoided hyperacute rejection and showed no antibody-mediated rejection for two days, but antigen regeneration coincided with immune injury from day three. Duration of conversion therefore matters alongside initial removal of the surface markers.
The blood programme has a different evidence base. The swine study tested laboratory aliquots under specified enzyme concentrations and exposure conditions, measuring antigen signal and blood quality. It did not test transfusion into recipients. Progress toward clinical use involves manufacturing consistency, the conversion process and the clinical-development programme advancing together.
Kemp's process-development work and the federal project create concrete avenues for manufacturing, preclinical and clinical-development collaboration. DIANA and the company-reported PwC Scale Medical Resilience programme provide acceleration and engagement contexts; clinical authorization remains a separate path.
Avivo is based in Vancouver, British Columbia, as recorded in ISED agreement 515732. Its development network extends beyond Canada: enzyme process-development partner Kemp Proteins is in Frederick, Maryland. That partnership concerns expression, purification and manufacturing-process optimization; it does not establish a qualified commercial production line or an exclusively Canadian manufacturing chain.
Vancouver, British Columbia is the published city-level context for Avivo Biomedical. It does not imply a street address or exact facility location.
Open the mapAvivo connects enzyme-based ABO-conversion research with a defined manufacturing and clinical-development programme. Kidney studies and laboratory whole-blood work show why compatibility could be improved, while antigen regeneration in the decedent study identifies a consequential limit. Kemp Proteins and a new federal contribution support the next development stages. The useful collaboration questions concern persistence, preservation of blood or organ function, and a reproducible process that can progress toward clinical use.
Interpretation of the public record. Not qualification, endorsement or evidence of buyer interest.
Preclinical enzyme-enabled blood and organ compatibility platform
Sep 18, 2026
On September 18, 2026, ISED announced up to C$10.9 million toward Avivo’s C$33.9 million project to advance blood-transfusion and organ-transplant technology. The associated contribution describes scale-up, preclinical studies and planned first-in-human trials through March 2030. The announcement does not establish that trials have begun.
Investigational blood- and organ-conversion technology, with preclinical evidence, enzyme process development and funded plans for first-in-human trials. Research, manufacturing and clinical-development collaboration are relevant; an authorized product or initiated human trial is not established by the inspected sources.
On September 18, 2026, ISED announced up to C$10.9 million toward Avivo's C$33.9 million blood-transfusion and organ-transplant technology project. The detailed record lists contribution agreement 515732 at C$10,994,000, from January 1, 2026 to March 31, 2030. Its scope includes scaling production, completing preclinical studies and launching first-in-human trials. The project value does not establish that all financing is committed, and the record does not disclose amounts already paid.
Under its former ABOzymes name, the company announced completion of seed financing in June 2022 without disclosing the amount or investors, alongside earlier pre-seed and nondilutive support. A US$5 million US Air Force grant mentioned in that release supported UBC academic collaborators and is not included as company financing. No current cash balance or company revenue is established by these disclosures.
2026 cohort participant
NATO DIANA
Avivo's public media page reports selection to NATO DIANA's 2026 innovator cohort; the candidate records program participation only and does not infer a military customer or medical authorization.
Life Sciences Fund contribution
Sep 18, 2026$10,994,000
ISED contribution agreement 515732 records C$10,994,000 for January 1, 2026 to March 31, 2030, supporting production scale-up, preclinical work and planned first-in-human trials. The September 18 announcement describes up to C$10.9 million toward a C$33.9 million project. Neither source establishes disbursement or fully committed project finance.
Kidney studies show initial antigen removal and short-term protection, followed by antigen regeneration in the decedent experiment. Whole-blood evidence comes from laboratory swine samples; the federal project proposes scale-up and first-in-human trials.
These records support the organization, its owned capabilities and their reviewed connections. A source count is not a count of independent confirmations.
Nature Biomedical Engineering · Oct 3, 2025
Source type: official report
Supports: Profile · executive relevance summary
Source location: executiveRelevanceSummary
In a human-decedent experiment, an enzyme-treated type-A kidney was transplanted into a type-O brain-dead recipient with a high anti-A titre. Hyperacute rejection was absent and antibody-mediated rejection was not observed for two days. A-antigen regeneration coincided with lesions and complement deposition from day three. This does not establish durable conversion or efficacy in living recipients; full supplemental protocol was not retrieved.
Supports: Profile · description
In a human-decedent experiment, an enzyme-treated type-A kidney was transplanted into a type-O brain-dead recipient with a high anti-A titre. Hyperacute rejection was absent and antibody-mediated rejection was not observed for two days. A-antigen regeneration coincided with lesions and complement deposition from day three. This does not establish durable conversion or efficacy in living recipients; full supplemental protocol was not retrieved.
Supports: Profile · reviewed questions.avivo-biomedical-decision-1.context
In a human-decedent experiment, an enzyme-treated type-A kidney was transplanted into a type-O brain-dead recipient with a high anti-A titre. Hyperacute rejection was absent and antibody-mediated rejection was not observed for two days. A-antigen regeneration coincided with lesions and complement deposition from day three. This does not establish durable conversion or efficacy in living recipients; full supplemental protocol was not retrieved.
Supports: Profile · reviewed questions.avivo-biomedical-decision-1.id
In a human-decedent experiment, an enzyme-treated type-A kidney was transplanted into a type-O brain-dead recipient with a high anti-A titre. Hyperacute rejection was absent and antibody-mediated rejection was not observed for two days. A-antigen regeneration coincided with lesions and complement deposition from day three. This does not establish durable conversion or efficacy in living recipients; full supplemental protocol was not retrieved.
Supports: Profile · commercial status
In a human-decedent experiment, an enzyme-treated type-A kidney was transplanted into a type-O brain-dead recipient with a high anti-A titre. Hyperacute rejection was absent and antibody-mediated rejection was not observed for two days. A-antigen regeneration coincided with lesions and complement deposition from day three. This does not establish durable conversion or efficacy in living recipients; full supplemental protocol was not retrieved.
Supports: Profile · reviewed questions.avivo-biomedical-decision-1.question
In a human-decedent experiment, an enzyme-treated type-A kidney was transplanted into a type-O brain-dead recipient with a high anti-A titre. Hyperacute rejection was absent and antibody-mediated rejection was not observed for two days. A-antigen regeneration coincided with lesions and complement deposition from day three. This does not establish durable conversion or efficacy in living recipients; full supplemental protocol was not retrieved.
Supports: Profile · operating context
In a human-decedent experiment, an enzyme-treated type-A kidney was transplanted into a type-O brain-dead recipient with a high anti-A titre. Hyperacute rejection was absent and antibody-mediated rejection was not observed for two days. A-antigen regeneration coincided with lesions and complement deposition from day three. This does not establish durable conversion or efficacy in living recipients; full supplemental protocol was not retrieved.
Supports: Profile · reviewed questions.avivo-biomedical-decision-1.confidence
In a human-decedent experiment, an enzyme-treated type-A kidney was transplanted into a type-O brain-dead recipient with a high anti-A titre. Hyperacute rejection was absent and antibody-mediated rejection was not observed for two days. A-antigen regeneration coincided with lesions and complement deposition from day three. This does not establish durable conversion or efficacy in living recipients; full supplemental protocol was not retrieved.
Supports: Universal blood-type conversion platform · update child
A converted kidney avoided hyperacute rejection in a type-O brain-dead recipient, but antigen regeneration and immune-mediated signs appeared after the initial two-day period.
Supports: Universal blood-type conversion platform · summary
In a human-decedent experiment, an enzyme-treated type-A kidney was transplanted into a type-O brain-dead recipient with a high anti-A titre. Hyperacute rejection was absent and antibody-mediated rejection was not observed for two days. A-antigen regeneration coincided with lesions and complement deposition from day three. This does not establish durable conversion or efficacy in living recipients; full supplemental protocol was not retrieved.
Supports: Universal blood-type conversion platform · maturity
In a human-decedent experiment, an enzyme-treated type-A kidney was transplanted into a type-O brain-dead recipient with a high anti-A titre. Hyperacute rejection was absent and antibody-mediated rejection was not observed for two days. A-antigen regeneration coincided with lesions and complement deposition from day three. This does not establish durable conversion or efficacy in living recipients; full supplemental protocol was not retrieved.
Innovation Science and Economic Development Canada
Source type: award or contract
Supports: Profile · legal name
ISED agreement 515732 records a C$10,994,000 contribution to Avivo Biomedical Inc., legal and operating name, for January 1, 2026 to March 31, 2030. The project proposes scaling production, completing preclinical studies and launching first-in-human clinical trials for a dual-use universal blood and organ platform. It lists Vancouver, British Columbia. Payment schedules, milestone conditions and disbursement amounts are not disclosed in the record.
Supports: Profile · disclosed financing summary
ISED agreement 515732 records a C$10,994,000 contribution to Avivo Biomedical Inc., legal and operating name, for January 1, 2026 to March 31, 2030. The project proposes scaling production, completing preclinical studies and launching first-in-human clinical trials for a dual-use universal blood and organ platform. It lists Vancouver, British Columbia. Payment schedules, milestone conditions and disbursement amounts are not disclosed in the record.
Transfusion / PubMed · Dec 24, 2025
Source type: official report
Supports: Profile · reviewed questions.avivo-biomedical-decision-1.confidence
The swine whole-blood study used blood from 16 type-A and four type-O pigs, 45 mL aliquots, and two enzymes at different concentrations, temperatures and exposure times. At 17.5 micrograms/mL after 15 minutes, A-antigen signal was 0.6%±0.2%, close to type-O control 0.45%±0.45%. The abstract reports stable laboratory blood-quality measures, including counts, blood gases and clotting tests. It describes laboratory conversion, not in-vivo transfusion or a human clinical product. University, military-academic and Avivo authors participated.
Supports: Profile · reviewed questions.avivo-biomedical-decision-1.context
The swine whole-blood study used blood from 16 type-A and four type-O pigs, 45 mL aliquots, and two enzymes at different concentrations, temperatures and exposure times. At 17.5 micrograms/mL after 15 minutes, A-antigen signal was 0.6%±0.2%, close to type-O control 0.45%±0.45%. The abstract reports stable laboratory blood-quality measures, including counts, blood gases and clotting tests. It describes laboratory conversion, not in-vivo transfusion or a human clinical product. University, military-academic and Avivo authors participated.
Innovation Science and Economic Development Canada · Sep 18, 2026
Source type: official policy
Supports: Profile · executive relevance summary
Source location: executiveRelevanceSummary
ISED announced on September 18, 2026 that Avivo Biomedical Inc. of British Columbia will receive up to C$10.9 million toward its C$33.9 million project advancing blood-transfusion and organ-transplant technology. The announcement is not proof that the full contribution has been paid or that the whole project is financed.
Supports: Profile · current activity
Kemp Proteins · Jun 2, 2026
Source type: official company news
Supports: Profile · commercial status
Kemp Proteins announced that Avivo selected it for upstream and downstream process optimization, recombinant-protein expression, purification strategy and scalable bioprocessing. Kemp is based in Frederick, Maryland. The release says Avivo is advancing toward first-in-human trials, not that trials have begun or a production process has been qualified.
Public sources cited · Facts and assessments kept separate · Human review
Supports: Profile · reviewed questions.avivo-biomedical-decision-1.confidence
ISED agreement 515732 records a C$10,994,000 contribution to Avivo Biomedical Inc., legal and operating name, for January 1, 2026 to March 31, 2030. The project proposes scaling production, completing preclinical studies and launching first-in-human clinical trials for a dual-use universal blood and organ platform. It lists Vancouver, British Columbia. Payment schedules, milestone conditions and disbursement amounts are not disclosed in the record.
Supports: Profile · reviewed questions.avivo-biomedical-decision-1.context
ISED agreement 515732 records a C$10,994,000 contribution to Avivo Biomedical Inc., legal and operating name, for January 1, 2026 to March 31, 2030. The project proposes scaling production, completing preclinical studies and launching first-in-human clinical trials for a dual-use universal blood and organ platform. It lists Vancouver, British Columbia. Payment schedules, milestone conditions and disbursement amounts are not disclosed in the record.
Supports: Profile · current activity
ISED agreement 515732 records a C$10,994,000 contribution to Avivo Biomedical Inc., legal and operating name, for January 1, 2026 to March 31, 2030. The project proposes scaling production, completing preclinical studies and launching first-in-human clinical trials for a dual-use universal blood and organ platform. It lists Vancouver, British Columbia. Payment schedules, milestone conditions and disbursement amounts are not disclosed in the record.
Supports: Profile · commercial status
ISED agreement 515732 records a C$10,994,000 contribution to Avivo Biomedical Inc., legal and operating name, for January 1, 2026 to March 31, 2030. The project proposes scaling production, completing preclinical studies and launching first-in-human clinical trials for a dual-use universal blood and organ platform. It lists Vancouver, British Columbia. Payment schedules, milestone conditions and disbursement amounts are not disclosed in the record.
Supports: Profile · operating context
ISED agreement 515732 records a C$10,994,000 contribution to Avivo Biomedical Inc., legal and operating name, for January 1, 2026 to March 31, 2030. The project proposes scaling production, completing preclinical studies and launching first-in-human clinical trials for a dual-use universal blood and organ platform. It lists Vancouver, British Columbia. Payment schedules, milestone conditions and disbursement amounts are not disclosed in the record.
Supports: Profile · reviewed questions.avivo-biomedical-decision-1.id
ISED agreement 515732 records a C$10,994,000 contribution to Avivo Biomedical Inc., legal and operating name, for January 1, 2026 to March 31, 2030. The project proposes scaling production, completing preclinical studies and launching first-in-human clinical trials for a dual-use universal blood and organ platform. It lists Vancouver, British Columbia. Payment schedules, milestone conditions and disbursement amounts are not disclosed in the record.
Supports: Profile · reviewed questions.avivo-biomedical-decision-1.question
ISED agreement 515732 records a C$10,994,000 contribution to Avivo Biomedical Inc., legal and operating name, for January 1, 2026 to March 31, 2030. The project proposes scaling production, completing preclinical studies and launching first-in-human clinical trials for a dual-use universal blood and organ platform. It lists Vancouver, British Columbia. Payment schedules, milestone conditions and disbursement amounts are not disclosed in the record.
Supports: Profile · canadian footprint
ISED agreement 515732 records a C$10,994,000 contribution to Avivo Biomedical Inc., legal and operating name, for January 1, 2026 to March 31, 2030. The project proposes scaling production, completing preclinical studies and launching first-in-human clinical trials for a dual-use universal blood and organ platform. It lists Vancouver, British Columbia. Payment schedules, milestone conditions and disbursement amounts are not disclosed in the record.
Supports: Universal blood-type conversion platform · maturity
ISED agreement 515732 records a C$10,994,000 contribution to Avivo Biomedical Inc., legal and operating name, for January 1, 2026 to March 31, 2030. The project proposes scaling production, completing preclinical studies and launching first-in-human clinical trials for a dual-use universal blood and organ platform. It lists Vancouver, British Columbia. Payment schedules, milestone conditions and disbursement amounts are not disclosed in the record.
Supports: Universal blood-type conversion platform · summary
ISED agreement 515732 records a C$10,994,000 contribution to Avivo Biomedical Inc., legal and operating name, for January 1, 2026 to March 31, 2030. The project proposes scaling production, completing preclinical studies and launching first-in-human clinical trials for a dual-use universal blood and organ platform. It lists Vancouver, British Columbia. Payment schedules, milestone conditions and disbursement amounts are not disclosed in the record.
Supports: Universal blood-type conversion platform · commercial availability
ISED agreement 515732 records a C$10,994,000 contribution to Avivo Biomedical Inc., legal and operating name, for January 1, 2026 to March 31, 2030. The project proposes scaling production, completing preclinical studies and launching first-in-human clinical trials for a dual-use universal blood and organ platform. It lists Vancouver, British Columbia. Payment schedules, milestone conditions and disbursement amounts are not disclosed in the record.
Supports: Life Sciences Fund contribution funding event
ISED agreement 515732 records a C$10,994,000 contribution to Avivo Biomedical Inc., legal and operating name, for January 1, 2026 to March 31, 2030. The project proposes scaling production, completing preclinical studies and launching first-in-human clinical trials for a dual-use universal blood and organ platform. It lists Vancouver, British Columbia. Payment schedules, milestone conditions and disbursement amounts are not disclosed in the record.
Supports: Life Sciences Fund contribution funding event
ISED agreement 515732 records a C$10,994,000 contribution to Avivo Biomedical Inc., legal and operating name, for January 1, 2026 to March 31, 2030. The project proposes scaling production, completing preclinical studies and launching first-in-human clinical trials for a dual-use universal blood and organ platform. It lists Vancouver, British Columbia. Payment schedules, milestone conditions and disbursement amounts are not disclosed in the record.
Supports: Life Sciences Fund contribution funding event
ISED agreement 515732 records a C$10,994,000 contribution to Avivo Biomedical Inc., legal and operating name, for January 1, 2026 to March 31, 2030. The project proposes scaling production, completing preclinical studies and launching first-in-human clinical trials for a dual-use universal blood and organ platform. It lists Vancouver, British Columbia. Payment schedules, milestone conditions and disbursement amounts are not disclosed in the record.
Supports: Life Sciences Fund contribution funding event
ISED agreement 515732 records a C$10,994,000 contribution to Avivo Biomedical Inc., legal and operating name, for January 1, 2026 to March 31, 2030. The project proposes scaling production, completing preclinical studies and launching first-in-human clinical trials for a dual-use universal blood and organ platform. It lists Vancouver, British Columbia. Payment schedules, milestone conditions and disbursement amounts are not disclosed in the record.
Supports: Profile · reviewed questions.avivo-biomedical-decision-1.question
The swine whole-blood study used blood from 16 type-A and four type-O pigs, 45 mL aliquots, and two enzymes at different concentrations, temperatures and exposure times. At 17.5 micrograms/mL after 15 minutes, A-antigen signal was 0.6%±0.2%, close to type-O control 0.45%±0.45%. The abstract reports stable laboratory blood-quality measures, including counts, blood gases and clotting tests. It describes laboratory conversion, not in-vivo transfusion or a human clinical product. University, military-academic and Avivo authors participated.
Supports: Profile · reviewed questions.avivo-biomedical-decision-1.id
The swine whole-blood study used blood from 16 type-A and four type-O pigs, 45 mL aliquots, and two enzymes at different concentrations, temperatures and exposure times. At 17.5 micrograms/mL after 15 minutes, A-antigen signal was 0.6%±0.2%, close to type-O control 0.45%±0.45%. The abstract reports stable laboratory blood-quality measures, including counts, blood gases and clotting tests. It describes laboratory conversion, not in-vivo transfusion or a human clinical product. University, military-academic and Avivo authors participated.
Supports: Profile · executive relevance summary
Source location: executiveRelevanceSummary
The swine whole-blood study used blood from 16 type-A and four type-O pigs, 45 mL aliquots, and two enzymes at different concentrations, temperatures and exposure times. At 17.5 micrograms/mL after 15 minutes, A-antigen signal was 0.6%±0.2%, close to type-O control 0.45%±0.45%. The abstract reports stable laboratory blood-quality measures, including counts, blood gases and clotting tests. It describes laboratory conversion, not in-vivo transfusion or a human clinical product. University, military-academic and Avivo authors participated.
Supports: Profile · operating context
The swine whole-blood study used blood from 16 type-A and four type-O pigs, 45 mL aliquots, and two enzymes at different concentrations, temperatures and exposure times. At 17.5 micrograms/mL after 15 minutes, A-antigen signal was 0.6%±0.2%, close to type-O control 0.45%±0.45%. The abstract reports stable laboratory blood-quality measures, including counts, blood gases and clotting tests. It describes laboratory conversion, not in-vivo transfusion or a human clinical product. University, military-academic and Avivo authors participated.
Supports: Profile · description
The swine whole-blood study used blood from 16 type-A and four type-O pigs, 45 mL aliquots, and two enzymes at different concentrations, temperatures and exposure times. At 17.5 micrograms/mL after 15 minutes, A-antigen signal was 0.6%±0.2%, close to type-O control 0.45%±0.45%. The abstract reports stable laboratory blood-quality measures, including counts, blood gases and clotting tests. It describes laboratory conversion, not in-vivo transfusion or a human clinical product. University, military-academic and Avivo authors participated.
Supports: Universal blood-type conversion platform · summary
The swine whole-blood study used blood from 16 type-A and four type-O pigs, 45 mL aliquots, and two enzymes at different concentrations, temperatures and exposure times. At 17.5 micrograms/mL after 15 minutes, A-antigen signal was 0.6%±0.2%, close to type-O control 0.45%±0.45%. The abstract reports stable laboratory blood-quality measures, including counts, blood gases and clotting tests. It describes laboratory conversion, not in-vivo transfusion or a human clinical product. University, military-academic and Avivo authors participated.
Supports: Universal blood-type conversion platform · maturity
The swine whole-blood study used blood from 16 type-A and four type-O pigs, 45 mL aliquots, and two enzymes at different concentrations, temperatures and exposure times. At 17.5 micrograms/mL after 15 minutes, A-antigen signal was 0.6%±0.2%, close to type-O control 0.45%±0.45%. The abstract reports stable laboratory blood-quality measures, including counts, blood gases and clotting tests. It describes laboratory conversion, not in-vivo transfusion or a human clinical product. University, military-academic and Avivo authors participated.
Supports: Universal blood-type conversion platform · core features
The swine whole-blood study used blood from 16 type-A and four type-O pigs, 45 mL aliquots, and two enzymes at different concentrations, temperatures and exposure times. At 17.5 micrograms/mL after 15 minutes, A-antigen signal was 0.6%±0.2%, close to type-O control 0.45%±0.45%. The abstract reports stable laboratory blood-quality measures, including counts, blood gases and clotting tests. It describes laboratory conversion, not in-vivo transfusion or a human clinical product. University, military-academic and Avivo authors participated.
ISED announced on September 18, 2026 that Avivo Biomedical Inc. of British Columbia will receive up to C$10.9 million toward its C$33.9 million project advancing blood-transfusion and organ-transplant technology. The announcement is not proof that the full contribution has been paid or that the whole project is financed.
Supports: Profile · disclosed financing summary
ISED announced on September 18, 2026 that Avivo Biomedical Inc. of British Columbia will receive up to C$10.9 million toward its C$33.9 million project advancing blood-transfusion and organ-transplant technology. The announcement is not proof that the full contribution has been paid or that the whole project is financed.
Supports: Profile · description
ISED announced on September 18, 2026 that Avivo Biomedical Inc. of British Columbia will receive up to C$10.9 million toward its C$33.9 million project advancing blood-transfusion and organ-transplant technology. The announcement is not proof that the full contribution has been paid or that the whole project is financed.
Supports: Profile · current activity as of
ISED announced on September 18, 2026 that Avivo Biomedical Inc. of British Columbia will receive up to C$10.9 million toward its C$33.9 million project advancing blood-transfusion and organ-transplant technology. The announcement is not proof that the full contribution has been paid or that the whole project is financed.
Supports: Life Sciences Fund contribution funding event
ISED announced on September 18, 2026 that Avivo Biomedical Inc. of British Columbia will receive up to C$10.9 million toward its C$33.9 million project advancing blood-transfusion and organ-transplant technology. The announcement is not proof that the full contribution has been paid or that the whole project is financed.
Supports: Life Sciences Fund contribution funding event
ISED announced on September 18, 2026 that Avivo Biomedical Inc. of British Columbia will receive up to C$10.9 million toward its C$33.9 million project advancing blood-transfusion and organ-transplant technology. The announcement is not proof that the full contribution has been paid or that the whole project is financed.
Supports: Profile · canadian footprint
Kemp Proteins announced that Avivo selected it for upstream and downstream process optimization, recombinant-protein expression, purification strategy and scalable bioprocessing. Kemp is based in Frederick, Maryland. The release says Avivo is advancing toward first-in-human trials, not that trials have begun or a production process has been qualified.
Supports: Profile · description
Kemp Proteins announced that Avivo selected it for upstream and downstream process optimization, recombinant-protein expression, purification strategy and scalable bioprocessing. Kemp is based in Frederick, Maryland. The release says Avivo is advancing toward first-in-human trials, not that trials have begun or a production process has been qualified.
Supports: Profile · operating context
Kemp Proteins announced that Avivo selected it for upstream and downstream process optimization, recombinant-protein expression, purification strategy and scalable bioprocessing. Kemp is based in Frederick, Maryland. The release says Avivo is advancing toward first-in-human trials, not that trials have begun or a production process has been qualified.
Supports: Profile · executive relevance summary
Source location: executiveRelevanceSummary
Kemp Proteins announced that Avivo selected it for upstream and downstream process optimization, recombinant-protein expression, purification strategy and scalable bioprocessing. Kemp is based in Frederick, Maryland. The release says Avivo is advancing toward first-in-human trials, not that trials have begun or a production process has been qualified.
Supports: Universal blood-type conversion platform · core features
Kemp Proteins announced that Avivo selected it for upstream and downstream process optimization, recombinant-protein expression, purification strategy and scalable bioprocessing. Kemp is based in Frederick, Maryland. The release says Avivo is advancing toward first-in-human trials, not that trials have begun or a production process has been qualified.
Supports: Universal blood-type conversion platform · commercial availability
Kemp Proteins announced that Avivo selected it for upstream and downstream process optimization, recombinant-protein expression, purification strategy and scalable bioprocessing. Kemp is based in Frederick, Maryland. The release says Avivo is advancing toward first-in-human trials, not that trials have begun or a production process has been qualified.
Supports: Universal blood-type conversion platform · summary
Kemp Proteins announced that Avivo selected it for upstream and downstream process optimization, recombinant-protein expression, purification strategy and scalable bioprocessing. Kemp is based in Frederick, Maryland. The release says Avivo is advancing toward first-in-human trials, not that trials have begun or a production process has been qualified.
Avivo Biomedical
Source type: official company product
Supports: Profile · reviewed questions.avivo-biomedical-decision-1.question
The reproduced peer-reviewed kidney abstract describes transplantation of an enzyme-converted type-A kidney into a type-O brain-dead recipient. Hyperacute rejection was absent and no antibody-mediated rejection was seen for two days; lesions and complement deposition appeared from day three alongside A-antigen regeneration. This limited decedent experiment does not demonstrate durable clinical compatibility in living recipients.
Supports: Profile · reviewed questions.avivo-biomedical-decision-1.confidence
The reproduced peer-reviewed kidney abstract describes transplantation of an enzyme-converted type-A kidney into a type-O brain-dead recipient. Hyperacute rejection was absent and no antibody-mediated rejection was seen for two days; lesions and complement deposition appeared from day three alongside A-antigen regeneration. This limited decedent experiment does not demonstrate durable clinical compatibility in living recipients.
Supports: Profile · reviewed questions.avivo-biomedical-decision-1.id
The reproduced peer-reviewed kidney abstract describes transplantation of an enzyme-converted type-A kidney into a type-O brain-dead recipient. Hyperacute rejection was absent and no antibody-mediated rejection was seen for two days; lesions and complement deposition appeared from day three alongside A-antigen regeneration. This limited decedent experiment does not demonstrate durable clinical compatibility in living recipients.
Supports: Profile · reviewed questions.avivo-biomedical-decision-1.context
The reproduced peer-reviewed kidney abstract describes transplantation of an enzyme-converted type-A kidney into a type-O brain-dead recipient. Hyperacute rejection was absent and no antibody-mediated rejection was seen for two days; lesions and complement deposition appeared from day three alongside A-antigen regeneration. This limited decedent experiment does not demonstrate durable clinical compatibility in living recipients.
Supports: Profile · operating context
The reproduced peer-reviewed kidney abstract describes transplantation of an enzyme-converted type-A kidney into a type-O brain-dead recipient. Hyperacute rejection was absent and no antibody-mediated rejection was seen for two days; lesions and complement deposition appeared from day three alongside A-antigen regeneration. This limited decedent experiment does not demonstrate durable clinical compatibility in living recipients.
Supports: Universal blood-type conversion platform · summary
The reproduced peer-reviewed kidney abstract describes transplantation of an enzyme-converted type-A kidney into a type-O brain-dead recipient. Hyperacute rejection was absent and no antibody-mediated rejection was seen for two days; lesions and complement deposition appeared from day three alongside A-antigen regeneration. This limited decedent experiment does not demonstrate durable clinical compatibility in living recipients.
Supports: Universal blood-type conversion platform · maturity
The reproduced peer-reviewed kidney abstract describes transplantation of an enzyme-converted type-A kidney into a type-O brain-dead recipient. Hyperacute rejection was absent and no antibody-mediated rejection was seen for two days; lesions and complement deposition appeared from day three alongside A-antigen regeneration. This limited decedent experiment does not demonstrate durable clinical compatibility in living recipients.
Supports: Universal blood-type conversion platform · core features
The reproduced peer-reviewed kidney abstract describes transplantation of an enzyme-converted type-A kidney into a type-O brain-dead recipient. Hyperacute rejection was absent and no antibody-mediated rejection was seen for two days; lesions and complement deposition appeared from day three alongside A-antigen regeneration. This limited decedent experiment does not demonstrate durable clinical compatibility in living recipients.
Supports: Universal blood-type conversion platform · technology readiness level
The reproduced peer-reviewed kidney abstract describes transplantation of an enzyme-converted type-A kidney into a type-O brain-dead recipient. Hyperacute rejection was absent and no antibody-mediated rejection was seen for two days; lesions and complement deposition appeared from day three alongside A-antigen regeneration. This limited decedent experiment does not demonstrate durable clinical compatibility in living recipients.
Supports: Universal blood-type conversion platform · capability type
The reproduced peer-reviewed kidney abstract describes transplantation of an enzyme-converted type-A kidney into a type-O brain-dead recipient. Hyperacute rejection was absent and no antibody-mediated rejection was seen for two days; lesions and complement deposition appeared from day three alongside A-antigen regeneration. This limited decedent experiment does not demonstrate durable clinical compatibility in living recipients.
Supports: Universal blood-type conversion platform · core features
The reproduced peer-reviewed kidney abstract describes transplantation of an enzyme-converted type-A kidney into a type-O brain-dead recipient. Hyperacute rejection was absent and no antibody-mediated rejection was seen for two days; lesions and complement deposition appeared from day three alongside A-antigen regeneration. This limited decedent experiment does not demonstrate durable clinical compatibility in living recipients.
Supports: Universal blood-type conversion platform · technical tags
The reproduced peer-reviewed kidney abstract describes transplantation of an enzyme-converted type-A kidney into a type-O brain-dead recipient. Hyperacute rejection was absent and no antibody-mediated rejection was seen for two days; lesions and complement deposition appeared from day three alongside A-antigen regeneration. This limited decedent experiment does not demonstrate durable clinical compatibility in living recipients.
Supports: Universal blood-type conversion platform · commercial availability
The reproduced peer-reviewed kidney abstract describes transplantation of an enzyme-converted type-A kidney into a type-O brain-dead recipient. Hyperacute rejection was absent and no antibody-mediated rejection was seen for two days; lesions and complement deposition appeared from day three alongside A-antigen regeneration. This limited decedent experiment does not demonstrate durable clinical compatibility in living recipients.
Supports: Universal blood-type conversion platform · technical tags
The reproduced peer-reviewed kidney abstract describes transplantation of an enzyme-converted type-A kidney into a type-O brain-dead recipient. Hyperacute rejection was absent and no antibody-mediated rejection was seen for two days; lesions and complement deposition appeared from day three alongside A-antigen regeneration. This limited decedent experiment does not demonstrate durable clinical compatibility in living recipients.
Supports: Universal blood-type conversion platform · technicaldomainslugs
The reproduced peer-reviewed kidney abstract describes transplantation of an enzyme-converted type-A kidney into a type-O brain-dead recipient. Hyperacute rejection was absent and no antibody-mediated rejection was seen for two days; lesions and complement deposition appeared from day three alongside A-antigen regeneration. This limited decedent experiment does not demonstrate durable clinical compatibility in living recipients.
Supports: Universal blood-type conversion platform · technicaldomainslugs
The reproduced peer-reviewed kidney abstract describes transplantation of an enzyme-converted type-A kidney into a type-O brain-dead recipient. Hyperacute rejection was absent and no antibody-mediated rejection was seen for two days; lesions and complement deposition appeared from day three alongside A-antigen regeneration. This limited decedent experiment does not demonstrate durable clinical compatibility in living recipients.
Supports: Universal blood-type conversion platform · technical tags
The reproduced peer-reviewed kidney abstract describes transplantation of an enzyme-converted type-A kidney into a type-O brain-dead recipient. Hyperacute rejection was absent and no antibody-mediated rejection was seen for two days; lesions and complement deposition appeared from day three alongside A-antigen regeneration. This limited decedent experiment does not demonstrate durable clinical compatibility in living recipients.
Supports: Universal blood-type conversion platform · defence applications
The reproduced peer-reviewed kidney abstract describes transplantation of an enzyme-converted type-A kidney into a type-O brain-dead recipient. Hyperacute rejection was absent and no antibody-mediated rejection was seen for two days; lesions and complement deposition appeared from day three alongside A-antigen regeneration. This limited decedent experiment does not demonstrate durable clinical compatibility in living recipients.
Supports: Universal blood-type conversion platform · technical tags
The reproduced peer-reviewed kidney abstract describes transplantation of an enzyme-converted type-A kidney into a type-O brain-dead recipient. Hyperacute rejection was absent and no antibody-mediated rejection was seen for two days; lesions and complement deposition appeared from day three alongside A-antigen regeneration. This limited decedent experiment does not demonstrate durable clinical compatibility in living recipients.
Supports: Universal blood-type conversion platform · technical tags
The reproduced peer-reviewed kidney abstract describes transplantation of an enzyme-converted type-A kidney into a type-O brain-dead recipient. Hyperacute rejection was absent and no antibody-mediated rejection was seen for two days; lesions and complement deposition appeared from day three alongside A-antigen regeneration. This limited decedent experiment does not demonstrate durable clinical compatibility in living recipients.
Supports: Universal blood-type conversion platform · core features
The reproduced peer-reviewed kidney abstract describes transplantation of an enzyme-converted type-A kidney into a type-O brain-dead recipient. Hyperacute rejection was absent and no antibody-mediated rejection was seen for two days; lesions and complement deposition appeared from day three alongside A-antigen regeneration. This limited decedent experiment does not demonstrate durable clinical compatibility in living recipients.
Supports: Universal blood-type conversion platform · technical tags
The reproduced peer-reviewed kidney abstract describes transplantation of an enzyme-converted type-A kidney into a type-O brain-dead recipient. Hyperacute rejection was absent and no antibody-mediated rejection was seen for two days; lesions and complement deposition appeared from day three alongside A-antigen regeneration. This limited decedent experiment does not demonstrate durable clinical compatibility in living recipients.
Supports: Universal blood-type conversion platform · name
The reproduced peer-reviewed kidney abstract describes transplantation of an enzyme-converted type-A kidney into a type-O brain-dead recipient. Hyperacute rejection was absent and no antibody-mediated rejection was seen for two days; lesions and complement deposition appeared from day three alongside A-antigen regeneration. This limited decedent experiment does not demonstrate durable clinical compatibility in living recipients.
Source type: official company product
Supports: Profile · operating context
Kemp Proteins announced selection by Avivo on June 2, 2026 to support upstream/downstream process optimization and enzyme manufacturing development. The collaboration is associated with Avivo's NATO DIANA 2026 participation. It is a manufacturability and scale-up step, not clinical authorization, a licensed blood product or a military supply contract.
Supports: Universal blood-type conversion platform · summary
Kemp Proteins announced selection by Avivo on June 2, 2026 to support upstream/downstream process optimization and enzyme manufacturing development. The collaboration is associated with Avivo's NATO DIANA 2026 participation. It is a manufacturability and scale-up step, not clinical authorization, a licensed blood product or a military supply contract.
Avivo Biomedical
Source type: official company product
Supports: Profile · description
Avivo Biomedical is a Canadian biotechnology company developing enzyme-enabled approaches intended to convert donated blood and organs to universal type O and improve the availability of urgent treatment options.
Supports: Profile · reviewed questions.avivo-biomedical-first-conversation.question
True North Map derives this first-conversation question from the documented Avivo Biomedical capability, current evidence and the decision gap that remains.
Supports: Profile · reviewed questions.avivo-biomedical-first-conversation.context
Avivo Biomedical's public evidence establishes its current role and offering, but it does not answer every access, configuration, eligibility, maturity or buyer question needed for a first business-development conversation.
Supports: Profile · editorial profile version
Avivo Biomedical has sufficient mapped public evidence for private reviewer consideration of the shared editorial profile template.
Supports: Profile · operating context
Blood-type conversion enzymes; Whole-blood conversion research; Organ-conversion research; Compatibility with existing clinical workflows
Supports: Profile · profileData.publicContact.contactPageUrl
The official public contact pathway for Avivo Biomedical is https://avivobio.com/.
Supports: Profile · current activity
True North Map classifies the legacy undated product description as operating context rather than a material current development, so the optional Recent Activity field is cleared.
Supports: Profile · canadian footprint
Avivo Biomedical has a documented Canadian operating presence in Vancouver, British Columbia.
Supports: Universal blood-type conversion platform · summary
Avivo develops enzyme-enabled methods intended to convert type-A blood cells and donor organs to universal type O, with public materials describing translational research and potential use in hospital, remote, emergency and trauma settings.
Source type: official company product
Supports: Profile · description
Avivo describes enzymes that remove surface blood-group markers, with intended conversion of A, B and AB to type O. Proposed integration routes are enzymes added to blood-bag systems at collection for whole blood or red blood cells, and to preservation solutions during organ perfusion. The page says these routes will be integrated; it does not document a cleared clinical product.
Supports: Profile · executive relevance summary
Source location: executiveRelevanceSummary
Avivo describes enzymes that remove surface blood-group markers, with intended conversion of A, B and AB to type O. Proposed integration routes are enzymes added to blood-bag systems at collection for whole blood or red blood cells, and to preservation solutions during organ perfusion. The page says these routes will be integrated; it does not document a cleared clinical product.
Supports: Universal blood-type conversion platform · summary
Avivo describes enzymes that remove surface blood-group markers, with intended conversion of A, B and AB to type O. Proposed integration routes are enzymes added to blood-bag systems at collection for whole blood or red blood cells, and to preservation solutions during organ perfusion. The page says these routes will be integrated; it does not document a cleared clinical product.
Supports: Universal blood-type conversion platform · technical tags
Avivo describes enzymes that remove surface blood-group markers, with intended conversion of A, B and AB to type O. Proposed integration routes are enzymes added to blood-bag systems at collection for whole blood or red blood cells, and to preservation solutions during organ perfusion. The page says these routes will be integrated; it does not document a cleared clinical product.
Supports: Universal blood-type conversion platform · technical tags
Avivo describes enzymes that remove surface blood-group markers, with intended conversion of A, B and AB to type O. Proposed integration routes are enzymes added to blood-bag systems at collection for whole blood or red blood cells, and to preservation solutions during organ perfusion. The page says these routes will be integrated; it does not document a cleared clinical product.
Supports: Universal blood-type conversion platform · technical tags
Avivo describes enzymes that remove surface blood-group markers, with intended conversion of A, B and AB to type O. Proposed integration routes are enzymes added to blood-bag systems at collection for whole blood or red blood cells, and to preservation solutions during organ perfusion. The page says these routes will be integrated; it does not document a cleared clinical product.
Supports: Universal blood-type conversion platform · technicaldomainslugs
Avivo describes enzymes that remove surface blood-group markers, with intended conversion of A, B and AB to type O. Proposed integration routes are enzymes added to blood-bag systems at collection for whole blood or red blood cells, and to preservation solutions during organ perfusion. The page says these routes will be integrated; it does not document a cleared clinical product.
Supports: Universal blood-type conversion platform · core features
Avivo describes enzymes that remove surface blood-group markers, with intended conversion of A, B and AB to type O. Proposed integration routes are enzymes added to blood-bag systems at collection for whole blood or red blood cells, and to preservation solutions during organ perfusion. The page says these routes will be integrated; it does not document a cleared clinical product.
Supports: Universal blood-type conversion platform · technical tags
Avivo describes enzymes that remove surface blood-group markers, with intended conversion of A, B and AB to type O. Proposed integration routes are enzymes added to blood-bag systems at collection for whole blood or red blood cells, and to preservation solutions during organ perfusion. The page says these routes will be integrated; it does not document a cleared clinical product.
Supports: Universal blood-type conversion platform · technical tags
Avivo describes enzymes that remove surface blood-group markers, with intended conversion of A, B and AB to type O. Proposed integration routes are enzymes added to blood-bag systems at collection for whole blood or red blood cells, and to preservation solutions during organ perfusion. The page says these routes will be integrated; it does not document a cleared clinical product.
Supports: Universal blood-type conversion platform · technology readiness level
Avivo describes enzymes that remove surface blood-group markers, with intended conversion of A, B and AB to type O. Proposed integration routes are enzymes added to blood-bag systems at collection for whole blood or red blood cells, and to preservation solutions during organ perfusion. The page says these routes will be integrated; it does not document a cleared clinical product.
Supports: Universal blood-type conversion platform · technicaldomainslugs
Avivo describes enzymes that remove surface blood-group markers, with intended conversion of A, B and AB to type O. Proposed integration routes are enzymes added to blood-bag systems at collection for whole blood or red blood cells, and to preservation solutions during organ perfusion. The page says these routes will be integrated; it does not document a cleared clinical product.
Supports: Universal blood-type conversion platform · core features
Avivo describes enzymes that remove surface blood-group markers, with intended conversion of A, B and AB to type O. Proposed integration routes are enzymes added to blood-bag systems at collection for whole blood or red blood cells, and to preservation solutions during organ perfusion. The page says these routes will be integrated; it does not document a cleared clinical product.
Supports: Universal blood-type conversion platform · defence applications
Avivo describes enzymes that remove surface blood-group markers, with intended conversion of A, B and AB to type O. Proposed integration routes are enzymes added to blood-bag systems at collection for whole blood or red blood cells, and to preservation solutions during organ perfusion. The page says these routes will be integrated; it does not document a cleared clinical product.
Supports: Universal blood-type conversion platform · technical tags
Avivo describes enzymes that remove surface blood-group markers, with intended conversion of A, B and AB to type O. Proposed integration routes are enzymes added to blood-bag systems at collection for whole blood or red blood cells, and to preservation solutions during organ perfusion. The page says these routes will be integrated; it does not document a cleared clinical product.
Supports: Universal blood-type conversion platform · capability type
Avivo describes enzymes that remove surface blood-group markers, with intended conversion of A, B and AB to type O. Proposed integration routes are enzymes added to blood-bag systems at collection for whole blood or red blood cells, and to preservation solutions during organ perfusion. The page says these routes will be integrated; it does not document a cleared clinical product.
Supports: Universal blood-type conversion platform · name
Avivo describes enzymes that remove surface blood-group markers, with intended conversion of A, B and AB to type O. Proposed integration routes are enzymes added to blood-bag systems at collection for whole blood or red blood cells, and to preservation solutions during organ perfusion. The page says these routes will be integrated; it does not document a cleared clinical product.
Supports: Universal blood-type conversion platform · commercial availability
Avivo describes enzymes that remove surface blood-group markers, with intended conversion of A, B and AB to type O. Proposed integration routes are enzymes added to blood-bag systems at collection for whole blood or red blood cells, and to preservation solutions during organ perfusion. The page says these routes will be integrated; it does not document a cleared clinical product.
Avivo Biomedical
Source type: official company product
Supports: Profile · operating context
Avivo's public media page reports selection to NATO DIANA's 2026 innovator cohort; the candidate records program participation only and does not infer a military customer or medical authorization.
Supports: Profile · current activity
Avivo's public media page records NATO DIANA 2026 cohort selection and recent translational research announcements, while its company page describes ongoing work toward blood- and organ-type conversion.
Supports: Profile · profileData.currentActivity
Avivo's public media page records NATO DIANA 2026 cohort selection and recent translational research announcements, while its company page describes ongoing work toward blood- and organ-type conversion.
Supports: 2026 cohort participant relationship
Source location: relationships.0.publicSummary
Avivo's public media page reports selection to NATO DIANA's 2026 innovator cohort; the candidate records program participation only and does not infer a military customer or medical authorization.
Source type: official report
Supports: Profile · operating context
The Transfusion study reports laboratory conversion of type-A swine whole blood toward an O-like antigen profile, with blood-quality measurements comparable to controls under the studied conditions. It is animal-sample evidence, not human transfusion efficacy. Authors disclose Avivo equity and enzyme patents, and the paper expressly disclaims US defence endorsement.
Supports: Universal blood-type conversion platform · summary
The Transfusion study reports laboratory conversion of type-A swine whole blood toward an O-like antigen profile, with blood-quality measurements comparable to controls under the studied conditions. It is animal-sample evidence, not human transfusion efficacy. Authors disclose Avivo equity and enzyme patents, and the paper expressly disclaims US defence endorsement.
NATO DIANA
Source type: accelerator cohort directory
Supports: Profile · profile data
NATO DIANA lists Avivo's 2026 cohort solution as a whole-blood conversion unit intended to convert A, B, and AB whole blood into universal blood; Avivo describes a six-month acceleration and validation programme under Human Resilience and Biotechnologies.
Supports: Profile · description
NATO DIANA lists Avivo Biomedical Inc. of Canada in its 2026 Human Resilience and Biotechnology cohort, describing a whole-blood conversion unit intended to convert A, B and AB whole blood to universal blood. Cohort inclusion and the programme description do not establish field deployment, procurement or clinical authorization.
Supports: Profile · operating context
NATO DIANA lists Avivo Biomedical Inc. of Canada in its 2026 Human Resilience and Biotechnology cohort, describing a whole-blood conversion unit intended to convert A, B and AB whole blood to universal blood. Cohort inclusion and the programme description do not establish field deployment, procurement or clinical authorization.
Nature Communications · Mar 30, 2024
Source type: official report
Supports: Profile · description
The 2024 study used research-only type-A kidneys declined for transplant. Two Flavonifractor plautii enzymes, FpGalNAc deacetylase and FpGalactosaminidase, were delivered during normothermic or hypothermic machine perfusion. A-antigen levels fell about 80% as early as two hours. The ex-vivo ABO-incompatible model did not show anti-A binding or classical complement activation; it lacked coagulation factors and was not a living-recipient transplant.
Supports: Universal blood-type conversion platform · core features
The 2024 study used research-only type-A kidneys declined for transplant. Two Flavonifractor plautii enzymes, FpGalNAc deacetylase and FpGalactosaminidase, were delivered during normothermic or hypothermic machine perfusion. A-antigen levels fell about 80% as early as two hours. The ex-vivo ABO-incompatible model did not show anti-A binding or classical complement activation; it lacked coagulation factors and was not a living-recipient transplant.
Supports: Universal blood-type conversion platform · summary
The 2024 study used research-only type-A kidneys declined for transplant. Two Flavonifractor plautii enzymes, FpGalNAc deacetylase and FpGalactosaminidase, were delivered during normothermic or hypothermic machine perfusion. A-antigen levels fell about 80% as early as two hours. The ex-vivo ABO-incompatible model did not show anti-A binding or classical complement activation; it lacked coagulation factors and was not a living-recipient transplant.
Avivo Biomedical
Source type: official company product
Supports: Profile · operating context
Avivo describes investigational enzyme-enabled blood-type conversion for blood and organs, links an enzyme-converted kidney study in a human-decedent model, and announces selection to the NATO DIANA 2026 cohort. A decedent study and accelerator participation do not establish approval for living-patient treatment or deployable military medical use.
Avivo Biomedical · Sep 20, 2022
Source type: official company news
Supports: Profile · description
The September 20, 2022 company announcement says ABOzymes adopted the Avivo name, following its founding in 2020. It establishes brand continuity, not a standalone legal name-change filing. The current ISED contribution independently identifies Avivo Biomedical Inc. as the legal recipient.
ABOzymes / BioSpace · Jun 23, 2022
Source type: official company news
Supports: Profile · disclosed financing summary
ABOzymes announced a completed seed financing in June 2022 without disclosing the amount or investors. It referred to earlier pre-seed and nondilutive support. A US$5 million US Air Force grant mentioned in the release went to UBC academic collaborators, not necessarily to the company; it is not company financing.
Avivo Biomedical
Source type: official company product
Supports: Profile · operating context
Avivo announced selection as one of 20 companies for an eight-week PwC Scale Medical Resilience for Civil and Military Use programme on April 28, 2026. This is company-reported accelerator participation, not purchasing authority, product approval or proof of programme outcomes.
Supports: Profile · operating context
Avivo announced selection as one of 20 companies for an eight-week PwC Scale Medical Resilience for Civil and Military Use programme on April 28, 2026. This is company-reported accelerator participation, not purchasing authority, product approval or proof of programme outcomes.
Nature Communications · Mar 30, 2024
Source type: official report
Supports: Universal blood-type conversion platform · update child
Two Flavonifractor plautii enzymes removed approximately 80% of type-A endothelial antigen from human kidneys within two hours under normothermic or hypothermic machine perfusion.
